Related Experiment Video

Updated: Jul 9, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Antiepileptic drug development in children: considerations for a revisited strategy

Catherine Chiron1, Olivier Dulac, Gerard Pons

  • 1Inserm, U663, Paris, France.

Drugs
|December 18, 2007
PubMed

Insights

Pediatric epilepsies, especially infantile forms and epileptic encephalopathies, are neglected in drug trials. New approaches are needed for evaluating antiepileptic drugs (AEDs) in children, considering their unique developmental needs and ethical requirements.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology
  • Drug Development

Background:

  • European authorities recognize the need for evaluating new drugs in children.
  • Current antiepileptic drug (AED) trials primarily focus on focal epilepsy, neglecting infantile epilepsies and epileptic encephalopathies.
  • Infantile epilepsies are frequent, severe, and considered 'therapeutic orphans' due to limited research.

Purpose of the Study:

  • To address the deficit in therapeutic trials for childhood epilepsy syndromes.
  • To improve the feasibility and quality of AED evaluations in children while respecting ethical considerations.
  • To explore innovative approaches for evaluating AEDs in pediatric populations.

Main Methods:

  • Review of issues specific to pediatric epilepsies for randomized controlled trials (RCTs).
  • Assessment of the extent to which adult data can be extrapolated to children.
  • Examination of innovative methodologies for AED evaluation in children.

Main Results:

  • Pediatric epilepsies present unique challenges (heterogeneity, severity, cognitive impact, pharmacoresistance) due to brain development, requiring syndrome-specific guidelines.
  • Adult data extrapolation for efficacy is feasible in focal epilepsy, but infants require age-specific trials.
  • Epileptic encephalopathies necessitate distinct trials, and pharmacokinetic/safety data are crucial for all pediatric age groups.

Conclusions:

  • Specific guidelines are essential for evaluating AEDs in children, accounting for developmental factors.
  • Extrapolation of adult data has limitations, particularly for infants and specific epilepsy syndromes like epileptic encephalopathies.
  • Innovative RCT designs (small homogeneous groups, sequential designs) and population pharmacokinetics offer promising avenues for efficient pediatric drug evaluation.

More Related Videos

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...